30,887 Shares in Henry Schein, Inc. $HSIC Acquired by SEB Asset Management AB

SEB Asset Management AB purchased a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 30,887 shares of the company’s stock, valued at approximately $2,276,000.

Several other hedge funds have also added to or reduced their stakes in the business. CYBER HORNET ETFs LLC acquired a new position in shares of Henry Schein in the second quarter valued at $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein during the 2nd quarter worth about $27,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Henry Schein during the 4th quarter worth about $30,000. Federated Hermes Inc. bought a new stake in shares of Henry Schein during the 4th quarter worth about $32,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Henry Schein during the 4th quarter worth about $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Mizuho lowered their price target on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. BMO Capital Markets started coverage on Henry Schein in a report on Wednesday, July 8th. They set a “market perform” rating and a $85.00 price objective for the company. UBS Group reaffirmed a “neutral” rating and issued a $85.00 target price (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Citigroup assumed coverage on Henry Schein in a research note on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price on the stock. Finally, Morgan Stanley reissued an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $87.64.

Henry Schein Trading Down 0.3%

HSIC stock opened at $84.53 on Friday. Henry Schein, Inc. has a 52 week low of $61.94 and a 52 week high of $89.34. The company has a market capitalization of $9.63 billion, a PE ratio of 25.54, a price-to-earnings-growth ratio of 1.63 and a beta of 0.81. The company’s 50-day simple moving average is $80.72 and its 200 day simple moving average is $77.99. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The business’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts anticipate that Henry Schein, Inc. will post 5.32 earnings per share for the current year.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $69.19 per share, for a total transaction of $691,900.00. Following the completion of the transaction, the director owned 20,000 shares in the company, valued at approximately $1,383,800. This represents a 100.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.89% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.